NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said ... nervous as Trump seeks to lure pharma investment to US 7:16 AM UTC Healthcare & Pharmaceuticalscategory Bidding war ...

A Merck logo is shown on a scientist's lab coat ... as they should be able to bridge approval for all IV solid tumor indications in the US [with] this data. For switch dynamics, keep in mind ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs (shareholders) alleged that they bought MRK stock at artificially inflated ...

40% of Merck & Co., Inc.'s revenues are driven by cancer ... two new drugs by the time its >$20bn per annum selling drug lost US patent protection, and the two drugs - Skyrizi and Rinvoq, earned ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

I will continue by comparing the revenue growth rates of Merck and Bristol-Myers Squibb ... Keytruda's exclusivity in the next five years in the US and China, it is developing a subcutaneous ...

© Ukrainian News, 1997 - 2025. All rights reserved.Publication and distribution of Ukrainian News' products are strictly prohibited without prior written consent of ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.